Beijing SL Pharmaceutical Co Ltd Cash Flow Reinvestment Rate
Beijing SL Pharmaceutical Co Ltd cash flow reinvestment rate. Beijing SL Pharmaceutical Co Ltd (002038) has a Cash Flow Reinvestment Rate of 0.17x as of September 2025, reinvesting CN¥11.35 Million (capex CN¥11.35 Million ) from operating cash flow of CN¥66.55 Million. Explore cash flow to debt ratio of Beijing SL Pharmaceutical Co Ltd to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Beijing SL Pharmaceutical Co Ltd (2003–2025)
Cash flow reinvestment rate of Beijing SL Pharmaceutical Co Ltd from 2003 to 2025. Historical reinvestment intensity for Beijing SL Pharmaceutical Co Ltd across 23 annual periods. Explore Beijing SL Pharmaceutical Co Ltd capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Beijing SL Pharmaceutical Co Ltd Cash Flow Reinvestment Rate by Year (2003–2025)
Beijing SL Pharmaceutical Co Ltd cash flow reinvestment rate by year from 2003 to 2025. Year-by-year capital reinvestment analysis for Beijing SL Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see 002038 cash flow conversion.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.03x | CN¥265.61 Million | CN¥257.66 Million | CN¥192.97 Million | ▼ -33.1% |
| 2024 | 1.54x | CN¥347.57 Million | CN¥225.49 Million | CN¥347.38 Million | ▲ +160.9% |
| 2023 | 0.59x | CN¥271.93 Million | CN¥460.20 Million | CN¥218.36 Million | ▼ -67.3% |
| 2022 | 1.81x | CN¥703.89 Million | CN¥389.82 Million | CN¥163.49 Million | ▲ +252.7% |
| 2021 | 0.51x | CN¥237.87 Million | CN¥464.63 Million | CN¥236.91 Million | ▼ -73.9% |
| 2020 | 1.96x | CN¥816.62 Million | CN¥415.84 Million | CN¥255.95 Million | ▲ +238.9% |
| 2019 | 0.58x | CN¥385.77 Million | CN¥665.83 Million | CN¥272.78 Million | ▼ -37.8% |
| 2018 | 0.93x | CN¥451.84 Million | CN¥485.17 Million | CN¥227.37 Million | ▼ -23.1% |
| 2017 | 1.21x | CN¥460.83 Million | CN¥380.72 Million | CN¥229.65 Million | ▼ -34.6% |
| 2016 | 1.85x | CN¥734.87 Million | CN¥396.86 Million | CN¥164.21 Million | ▲ +109.2% |
| 2015 | 0.89x | CN¥446.93 Million | CN¥504.87 Million | CN¥129.68 Million | ▲ +172.6% |
| 2014 | 0.32x | CN¥151.01 Million | CN¥465.00 Million | CN¥151.01 Million | ▲ +3.1% |
| 2013 | 0.32x | CN¥109.48 Million | CN¥347.41 Million | CN¥109.48 Million | ▼ -49.3% |
| 2012 | 0.62x | CN¥247.89 Million | CN¥398.60 Million | CN¥247.89 Million | ▲ +94.6% |
| 2011 | 0.32x | CN¥73.05 Million | CN¥228.59 Million | CN¥73.05 Million | ▲ +76.8% |
| 2010 | 0.18x | CN¥43.04 Million | CN¥238.13 Million | CN¥43.04 Million | ▲ +3.5% |
| 2009 | 0.17x | CN¥30.46 Million | CN¥174.41 Million | CN¥30.46 Million | ▲ +43.7% |
| 2008 | 0.12x | CN¥23.61 Million | CN¥194.32 Million | CN¥23.61 Million | ▼ -59.7% |
| 2007 | 0.30x | CN¥26.61 Million | CN¥88.36 Million | CN¥26.61 Million | ▼ -73.3% |
| 2006 | 1.13x | CN¥64.95 Million | CN¥57.55 Million | CN¥64.95 Million | ▼ -34.0% |
| 2005 | 1.71x | CN¥81.24 Million | CN¥47.48 Million | CN¥81.24 Million | ▲ +201.6% |
| 2004 | 0.57x | CN¥17.73 Million | CN¥31.26 Million | CN¥17.73 Million | ▲ +5.5% |
| 2003 | 0.54x | CN¥16.43 Million | CN¥30.55 Million | CN¥16.43 Million | — |